Research team of association for cancer research’s experimental studies has shown that: combination of vitamin A’s derivative retinoic acid and antidepressant can be used for the treatment of leukemia, a common type of disease. The tretinoin is called as all-trans retinoic acid (ATRA) and it is a vitamin A derivative. It has been used successfully to treat a rare type of disease in acute myeloid leukemia (AML). But this drug does not have effect on some more common types of AML.

Leukemia and lymphoma research institute’s researchers explore the possible effect of tretinoin treatment of other types of leukemia patients. It shows that retinoic acid can be used in a variety of acute myeloid leukemia (AML) type. The key is to joint with anti-depressant drug known as anti-benzene ring propylamine (TCP).

Retinoic acid has a deadly rare type of leukemia a curable disease. We have now found a way to use these features powerful drug (accutane) to treat more and more common type of leukemia. Why does not respond to other types of leukemia, the drug until now, been a mystery. The study found that a has been commonly used as antidepressant drugs can reverse the above phenomenon. If these results can be replicated in patients, combination therapy is a very promising in a variety of leukemia treatment.

All-trans retinoic acid to stimulate leukemia cell maturation and natural death to play a role. AML did not respond to this drug may be shut down due to all-trans retinoic acid gene. The minoxidil research team is looking for a drug which can be used to restart the all-trans retinoic acid activity. Draw on the epigenetic drug does not directly play a role for the gene, but the role of genes is turned on or off the drug mode of action. The study found that TCP can inhibit an enzyme called LSD1, you can turn on the genes of all-trans retinoic acid and make cancer cells sensitive to all-trans retinoic acid.

With the commencement of the study, the researchers have drugs combination studies in patients with acute myeloid leukemia. And it has entered into the phase II clinical trials experimental stage. Each year, there are more than 2,200 people who were diagnosed with acute myeloid leukemia. It is characterized by the uncontrolled growth of immature white blood cells in the bone marrow.Source: